References
- Bushee JL, Liang G, Dunne CE, et al. (2014). Identification of saturated and unsaturated fatty acids released during microsomal incubations. Xenobiotica 44:687–95
- Dalvie D, Obach RS, Kang P, et al. (2009). Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357–68
- Eagling VA, Tjia JF, Back DJ. (1998). Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107–14
- Ito K, Houston JB. (2005). Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103–12
- James LP, Mayeux PR, Hinson JA. (2003). Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 31:1499–506
- Kilpatrick GJ, Smith TW. (2005). Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 25:521–44
- Ludden LK, Ludden TM, Collins JM, et al. (1997). Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation. J Pharmacol Exp Ther 282:391–6
- Manevski N, Moreolo PS, Yli-Kauhaluoma J, et al. (2011). Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9. Drug Metab Dispos 39:2117–29
- Miners JO, Knights KM, Houston JB, et al. (2006). In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531–9
- Mulder GJ. (1992). Pharmacological effects of drug conjugates: is morphine 6-glucuronide an exception? Trends Pharmacol Sci 13:302–4
- Odan M, Ishizuka N, Hiramatsu Y, et al. (2012). Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent. Bioorg Med Chem Lett 22:2803–6
- Riley RJ, McGinnity DF, Austin RP. (2005). A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304–11
- Rowland A, Elliot DJ, Knights KM, et al. (2008). The “albumin effect” and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos 36:870–7
- Rowland A, Gaganis P, Elliot DJ, et al. (2007). Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137–47
- Sekiguchi K, Fukumura K, Hasegawa H, et al. (2015). The metabolism and pharmacokinetics of [14C]-S-777469, a new cannabinoid receptor 2 selective agonist, in healthy human subjects. Xenobiotica 45:150–7
- Sekiguchi K, Kanazu T, Takeuchi M, et al. (2013). Non-clinical evaluation of the metabolism, pharmacokinetics and excretion of S-777469, a new cannabinoid receptor 2 selective agonist. Xenobiotica 45:150–7
- Tang C, Lin Y, Rodrigues AD, et al. (2002). Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug Metab Dispos 30:648–54
- Wattanachai N, Polasek TM, Heath TM, et al. (2011). In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. Eur J Clin Pharmacol 67:815–24
- Wattanachai N, Tassaneeyakul W, Rowland A, et al. (2012). Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance. Drug Metab Dispos 40:982–9
- Yao HT, Chang YW, Lan SJ, et al. (2006). The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci 79:2432–40